L'intérêt à découvert pour Global X NASDAQ 100 Covered Call ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Global X NASDAQ 100 Covered Call ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Global X NASDAQ 100 Covered Call ETF (NASDAQ:QYLD), Rapport sur les intérêts à découvert

Global X NASDAQ-100 Covered Call ETF

Global X NASDAQ 100 Covered Call ETF

Technology

Consumer Cyclical

Communication Services

Consumer Defensive

Healthcare

Industrials

Basic Materials

Energy

Utilities

Other

Financial Services

Real Estate

The Fund invests at least 80% of its total assets in the securities of the CBOE NASDAQ-100 BuyWrite V2 Index (the Underlying Index).The CBOE NASDAQ-100 BuyWrite Index (BXN Index) is a benchmark index that measures the performance of a theoretical portfolio that holds a portfolio of the stocks included in the NASDAQ-100 Index (Reference Index), and writes (or sells) a succession of one-month at-the-money Reference Index covered call options. The Underlying Index replicates the methodology used to calculate the BXN Index, with one exception: the written Reference Index covered call options are held until one day prior to the expiration dates (i.e., generally the Thursday preceding the third Friday of the month) and are liquidated at a volume-weighted average price determined at the close.

Apple Inc

Microsoft Corp

Nvidia  Corporation 

Amazon.Com Inc

Broadcom, Inc.

Meta Platforms, Inc.

Tesla Inc.

Alphabet Inc., Class A

Alphabet, Inc. - Class C

Tcostco Wholesale Corporation3.

Netflix Inc

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422933-1&amp;h=797587863&amp;u=https%3A%2F%2Fwww.viatris.com%2Fen&amp;a=Viatris+Inc.">Viatris Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of MR-107A-02 versus placebo and included an opioid comparator arm (tramadol 50mg&nbsp;q6h) to confirm the sensitivity of the pain model.
The primary endpoint in both trials was defined by the Sum of Pain Intensity Difference (SPID) based on the Numeric Rating Scale measured over 0-48 hours (SPID0-48h). Both trials evaluated the reduction in opioid usage that was defined by number of mean doses of opioid rescue medication and proportion of opioid-free patients over the combined in- and out-patient treatment phases.
In both studies, MR-107A-02 demonstrated statistically significant and clinically meaningful results. In particular:
<ul>
<li>Treatment with MR-107A-02 led to improvement in pain versus baseline compared to placebo (herniorrhaphy: LS mean difference in SPID0-48h between MR-107A-02 and placebo = 50.1 (95% CI: 35.4, 64.8; p&lt;0.001); bunionectomy: LS mean difference in SPID0-48h between MR-107A-02 and placebo = 82.7 (95% CI: 62.0, 103.4; p&lt;0.001)). &nbsp;</li>
<li>MR-107A-02 demonstrated notable reduction in opioid usage over the entire treatment phase by reducing opioid use versus placebo and by showing a higher number opioid-free patients than placebo (herniorrhaphy: MR-107A-02 treatment group had 72.6% opioid-free patients versus 58.6% in the placebo arm (p=0.002); bunionectomy: MR-107A-02 treatment group had 56.9% opioid-free patients versus 33.1% in the placebo arm (p&lt;0.001)). &nbsp;</li>
<li>Post-hoc analyses demonstrated significantly superior pain control (SPID0-48) of MR-107A-02 versus the opioid arm in both surgical models, which was supported by time to perceptible and time to meaningful pain relief. Significantly shorter time to perceptible and meaningful pain relief was observed for MR-107A-02 versus placebo and shorter or comparable to tramadol. &nbsp;</li>
<li>MR-107A-02 was generally well tolerated. In both studies, incidence of treatment emergent adverse events (TEAEs) was comparable to placebo in a post-surgical setting. Few severe TEAEs and severe adverse events (SAEs) were reported with a rate consistent with placebo. No TEAEs leading to death were reported.</li>
</ul>

News

VTRS

Viatris Reports Phase 3 Results for Fast-Acting Pain Drug, Shows Less Opioid Use

Somnigroup International Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.47 by 4.26 percent. The company reported quarterly sales of $1.60 billion which missed the analyst consensus estimate of $1.63 billion by 1.67 percent.

Earnings

Earnings Beats

Earnings Misses

Somnigroup International Inc. Common Stock Q1 Adj. EPS $0.49 Beats $0.47 Estimate, Sales $1.60B Miss $1.63B Estimate

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and maintains $38 price target.

Price Target

Reiteration

Analyst Ratings

LENZ

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.21 by 4.76 percent. This is a 4.76 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $67.67 million which missed the analyst consensus estimate of $69.47 million by 2.59 percent. This is a 2.35 percent increase over sales of $66.11 million the same period last year.

P10 Q1 Adj. EPS $0.20 Misses $0.21 Estimate, Sales $67.67M Miss $69.47M Estimate

WIIM

Zillow Group shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance with its midpoint below estimates.

SEZL

Sezzle Shares Are Trading Higher After The Company Reported Better Then Expected Q1 EPS And Sales

Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) affirms FY2025 sales outlook from $2.80 billion-$2.85 billion to $2.80 billion-$2.85 billion vs $2.83 billion estimate.

Guidance

PLTK

Playtika Holding Affirms FY2025 Sales Guidance of $2.80B-$2.85B vs $2.83B Est

TTEK

Tetra Tech shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance above estimates. Also, the company raised its FY25 sales guidance.

MELI

MercadoLibre shares are trading higher after the company reported better-than-expected Q1 financial results.

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) is looking for Q2 GAAP EPS of $(0.13)-$(0.05) vs $0.01 analyst estimate. sees sales of $70.000 million-$80.000 million vs $90.83 million analyst estimate.

ASPN

Aspen Aerogels Sees Q2 GAAP EPS $(0.13)-$(0.05) vs $0.01 Est; Sees Sales $70M-$80M vs $90.83M Est

Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.13 by 38.46 percent. This is a 42.86 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $706.00 million which beat the analyst consensus estimate of $699.67 million by 0.91 percent. This is a 8.42 percent increase over sales of $651.20 million the same period last year.

Playtika Holding Q1 EPS $0.08 Misses $0.13 Estimate, Sales $706.00M Beat $699.67M Estimate

Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.52 by 17.31 percent. This is a 3.17 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $440.54 million which beat the analyst consensus estimate of $412.67 million by 6.75 percent. This is a 6.30 percent decrease over sales of $470.17 million the same period last year.

CMRE

Costamare Q1 Adj. EPS $0.61 Beats $0.52 Estimate, Sales $440.54M Beat $412.67M Estimate

– These cardiovascular medicines have the potential to address a significant unmet medical need for over half a million Canadians
– HLS will leverage existing organizational capabilities and commercial infrastructure
– Already approved and commercially available in the U.S. and Europe,&nbsp;NEXLETOL/NEXLIZET are under regulatory review in Canada with a decision expected later this year
– Deal terms include $1 million paid upfront and additional milestone payments tied to achievement of regulatory, pricing, reimbursement and commercial sales objectives
TORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HLS#TSX">HLS</a>), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an agreement with Esperion Therapeutics Inc. ("Esperion") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) to in-license and commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Canada. All financial figures are in U.S. dollars unless otherwise stated.
In Q4 2024, Esperion submitted New Drug Submissions to Health Canada for both NEXLETOL and NEXLIZET1. Under this agreement, HLS will be responsible for obtaining Health Canada approval, which is expected by the end of 2025. NEXLETOL and NEXLIZET are oral medications currently available in the U.S. and several European countries. Initially approved by the U.S. Food and Drug Administration in 2020 to help reduce low-density lipoprotein cholesterol ("LDL-C") levels, their labels were expanded in 2024 to include broader indications for cardiovascular risk reduction in patients who are unable to take recommended statin therapy, supported by data from the CLEAR Outcomes trial.
Current estimates suggest there are over half a million Canadians who could potentially benefit from NEXLETOL or NEXLIZET. This includes patients with elevated LDL-C levels and who are either statin intolerant or who are not at their LDL-C goal despite being on combination therapy with statins and ezetimibe. &nbsp;&nbsp;

ESPR

TSX:HLS

HLS Therapeutics Agrees With Esperion Therapeutics To In-License And Commercialize NEXLETOL And NEXLIZET In Canada

LegalZoom.com shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance with its midpoint above estimates. Also, the company issued FY25 sales guidance above estimates.

Needham analyst Chris Pierce reiterates ACV Auctions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>) with a Buy and maintains $25 price target.

ACVA

Needham Reiterates Buy on ACV Auctions, Maintains $25 Price Target

Marriott Vacations Worldwide shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY25 adjusted EPS guidance.

ALLETE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALE#NYSE">ALE</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.04 by 6.73 percent. This is a 10.23 percent increase over earnings of $0.88 per share from the same period last year. The company reported $400.20 million in sales this quarter. This is a 0.77 percent decrease over sales of $403.30 million the same period last year.

ALLETE Q1 EPS $0.97 Misses $1.04 Estimate, Sales $400.20M Down From $403.30M YoY

Sunrun shares are trading higher after the company reported better-than-expected Q1 financial results.

<ul>
<li>Updated 2025 full year guidance for the following key financial metrics:
<ul>
<li>Net sales: Low single-digit decline on a constant currency basis, compared to low single-digit increase, previously</li>
<li>Underlying (Non-GAAP) income (loss) before income taxes: Low single-digit decline on a constant currency basis, compared to mid single-digit increase, previously</li>
<li>Underlying (Non-GAAP) diluted earnings per share: Low single-digit increase compared to high single-digit increase, previously</li>
<li>Capital expenditures: $650 million incurred, plus or minus 5% compared to $750 million, plus or minus 5%, previously</li>
<li>Underlying (Non-GAAP) free cash flow: $1.3 billion, plus or minus 10% remains unchanged</li>
</ul>
</li>
</ul>

Molson Coors Beverage Expects FY25 Net Sales Decline Of Low Single-Digit (Vs Prior Low Single-Digit Increase), Adj EPS Growth Of Low Single-Digit (Vs Prior High Single-Digit Increase)

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) sees Q2 sales of $320.000 million-$350.000 million vs $334.39 million analyst estimate.

ARHS

Arhaus Sees Q2 Sales $320.000M-$350.000M vs $334.39M Est

Comments

Global X NASDAQ 100 Covered Call ETF

Intérêt court

Global X NASDAQ 100 Covered Call ETF (NASDAQ:QYLD), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL